The Impact of Non-Adherence to Antihypertensive Drug Therapy
Medication non-adherence is a major healthcare barrier, especially among diseases that are largely asymptomatic, such as hypertension. The impact of poor medication adherence ranges from patient-specific adverse health outcomes to broader strains on health care system resources. The Centers for Dise...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Healthcare |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9032/11/22/2979 |
_version_ | 1797459107326722048 |
---|---|
author | Syed Karam Mustafa Gardezi William W. Aitken Mohammad Hashim Jilani |
author_facet | Syed Karam Mustafa Gardezi William W. Aitken Mohammad Hashim Jilani |
author_sort | Syed Karam Mustafa Gardezi |
collection | DOAJ |
description | Medication non-adherence is a major healthcare barrier, especially among diseases that are largely asymptomatic, such as hypertension. The impact of poor medication adherence ranges from patient-specific adverse health outcomes to broader strains on health care system resources. The Centers for Disease Control (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database was used to retrieve Centers for Medicare and Medicaid Services’ data pertaining to blood pressure (BP) medication adherence, socio-economic variables, and cardiovascular (CV) outcomes across the United States. Multivariable linear regression models were used to estimate the change in total CV deaths as a function of non-adherence to BP medications. For every percent increase in the non-adherence rate, the total number of CV deaths increased by 7.13 deaths per 100,000 adults (95% CI: 6.34–7.92), even after controlling for the percentage of residents with access to insurance, the percentage of residents who were eligible for Medicaid, the percentage of residents without a college education, median home value, income inequality, and the poverty rate (<i>p</i> < 0.001). There is a significant association between non-adherence to BP medications and total CV deaths. Even a one percent increase in the adherence rate in the United States could result in tens of thousands of preventable CV deaths. Based on recently published CDC data, this could also have a tremendous impact on health care costs. This provides compelling evidence for increased efforts to improve adherence. |
first_indexed | 2024-03-09T16:47:38Z |
format | Article |
id | doaj.art-25d67d6574474102991c7a51e0dc8f14 |
institution | Directory Open Access Journal |
issn | 2227-9032 |
language | English |
last_indexed | 2024-03-09T16:47:38Z |
publishDate | 2023-11-01 |
publisher | MDPI AG |
record_format | Article |
series | Healthcare |
spelling | doaj.art-25d67d6574474102991c7a51e0dc8f142023-11-24T14:44:53ZengMDPI AGHealthcare2227-90322023-11-011122297910.3390/healthcare11222979The Impact of Non-Adherence to Antihypertensive Drug TherapySyed Karam Mustafa Gardezi0William W. Aitken1Mohammad Hashim Jilani2TJ Samson Community Hospital, Glasgow, KY 42141, USADepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USADivision of Cardiovascular Health, University of Cincinnati Medical Center, Cincinnati, OH 45219, USAMedication non-adherence is a major healthcare barrier, especially among diseases that are largely asymptomatic, such as hypertension. The impact of poor medication adherence ranges from patient-specific adverse health outcomes to broader strains on health care system resources. The Centers for Disease Control (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database was used to retrieve Centers for Medicare and Medicaid Services’ data pertaining to blood pressure (BP) medication adherence, socio-economic variables, and cardiovascular (CV) outcomes across the United States. Multivariable linear regression models were used to estimate the change in total CV deaths as a function of non-adherence to BP medications. For every percent increase in the non-adherence rate, the total number of CV deaths increased by 7.13 deaths per 100,000 adults (95% CI: 6.34–7.92), even after controlling for the percentage of residents with access to insurance, the percentage of residents who were eligible for Medicaid, the percentage of residents without a college education, median home value, income inequality, and the poverty rate (<i>p</i> < 0.001). There is a significant association between non-adherence to BP medications and total CV deaths. Even a one percent increase in the adherence rate in the United States could result in tens of thousands of preventable CV deaths. Based on recently published CDC data, this could also have a tremendous impact on health care costs. This provides compelling evidence for increased efforts to improve adherence.https://www.mdpi.com/2227-9032/11/22/2979non-adherencecardiovascular diseasehypertensionmortality |
spellingShingle | Syed Karam Mustafa Gardezi William W. Aitken Mohammad Hashim Jilani The Impact of Non-Adherence to Antihypertensive Drug Therapy Healthcare non-adherence cardiovascular disease hypertension mortality |
title | The Impact of Non-Adherence to Antihypertensive Drug Therapy |
title_full | The Impact of Non-Adherence to Antihypertensive Drug Therapy |
title_fullStr | The Impact of Non-Adherence to Antihypertensive Drug Therapy |
title_full_unstemmed | The Impact of Non-Adherence to Antihypertensive Drug Therapy |
title_short | The Impact of Non-Adherence to Antihypertensive Drug Therapy |
title_sort | impact of non adherence to antihypertensive drug therapy |
topic | non-adherence cardiovascular disease hypertension mortality |
url | https://www.mdpi.com/2227-9032/11/22/2979 |
work_keys_str_mv | AT syedkarammustafagardezi theimpactofnonadherencetoantihypertensivedrugtherapy AT williamwaitken theimpactofnonadherencetoantihypertensivedrugtherapy AT mohammadhashimjilani theimpactofnonadherencetoantihypertensivedrugtherapy AT syedkarammustafagardezi impactofnonadherencetoantihypertensivedrugtherapy AT williamwaitken impactofnonadherencetoantihypertensivedrugtherapy AT mohammadhashimjilani impactofnonadherencetoantihypertensivedrugtherapy |